AVISTA is pleased to be one of the participating companies, once again, in the Heep Yunn School Work Experience Placement Programme. From 4th to 7th of January 2022, four students from Heep Yunn School were assigned to work in AVISTA Hong Kong office full day to have a hands-on experience in the workplace and get to know about the day-to-day operations in the valuation and advisory industry. Pleased to be engaged in the programme and to make work immersion available, we hope to empower the younger generations to start building essential work skills that can help them make more informed career choices and improve their employment prospects.  <img src="../../../../../uploads/IMG_4054_349b0fd654.jpg" alt="" width="533" height="400" />

pinwheel-1716620_1920

As a Participating Company in Heep Yunn School Work Experience Placement Programme

Sirnaomics Ltd. has been successfully listed on the Mainboard of HKSE on 30 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. Sirnaomics is an RNA therapeutics biopharmaceutical company. Founded in 2007 in the U.S., the company is the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic. With research and development centers in both China and the U.S., the company delivers pre-clinical and clinical stage products and focuses on the discovery and development of innovative drugs. Sirnaomics’ core product STP705 demonstrated efficacy and safety in an oncology Phase I/II clinical trial for non-melanoma skin cancer. STP705 was further advanced in a Phase IIb clinical trial for squamous cell carcinoma in situ (isSCC), a Phase II clinical trial for treatment of skin basal cell carcinoma (BCC), a Phase II clinical trial for treatment of keloid and a Phase I/II clinical trial for treatment of hypertrophic scar (HTS). Sirnaomics has initiated a Phase I clinical trial using STP705 for treatment of liver cancer (basket) through a local injection based on an independent IND approval from US FDA. In addition, Sirnaomics will further optimize its drug delivery technology platforms and strengthen its capabilities to manufacture its products in large scale to promote the rapid growth of different clinical stage product lines they have currently and in the future. <img src="../../../../../uploads/EN_c93f3c2aa4.jpg" alt="" width="533" height="400" />

Congratulations to Sirnaomics Ltd. (2257.HK) on its Successful Listing

Focuslight Technologies Inc. (Focuslight) has been successfully listed on the Science and Technology Innovation Board (STAR) of the Shanghai Stock Exchange (SSE)on 24 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. Founded in 2007, Focuslight is primarily engaged in the upstream laser industry, focusing on research and development, production, and sale of high-power semiconductor laser components and laser optical components. Their products are used as solid-state laser pump sources and fiber laser core components, and in high-end industrial manufacturing, medical health and other fields. Focuslight is currently expanding their share in the midstream segment of the laser industry, setting foot in the development, production and sales of photonic application modules and systems, intelligent drive assistance systems, semiconductor integrated circuit chip manufacturing process, display panel manufacturing and other emerging application areas. <img src="../../../../../uploads/congrat_ad_EN_Focuslight_ce6c305244.JPG" alt="" width="533" height="400" />

Congratulations to Focuslight Technologies Inc. (688167.SH) on its Successful Listing

Merry Christmas everyone! AVISTA wishes our clients and business community a happy and restful Christmas holiday with your family and friends. Thank you again for the continued commitment and hard work this year. We look forward to continuing our work together in the new year. <img src="../../../../../uploads/Xmas2021_9af82760d3.JPG" alt="" width="450" height="500" />

Christmas background.jpg

2021 Christmas Greetings from AVISTA Group

YCP Holdings (Global) Limited has been successfully listed on the Market of the High-Growth and Emerging Stocks (MOTHERS) section of the Tokyo Stock Exchange (TSE) on 21 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. YCP Holdings (Global) Limited provides advisory services to help multinational and local companies thrive in Asia. The Company primarily provides investment funding, industry expertise, and operational support to its portfolio companies. <img src="../../../../../uploads/EN_4d88c82962.JPG" alt="" width="533" height="400" />

Congratulations to YCP Holdings (Global) Limited (9257.TSE) on its Successful Listing

Qingci Games Inc. (QingCi) has been successfully listed on the Mainboard of HKSE on 16 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. QingCi is a leading mobile game developer and publisher in China, offering mobile games with captivating content as well as distinctive and fantastic gameplay experiences to players around the world. Their games are particularly popular among the young generation that is aged 30 or below. As a pioneer and leader in casual games, especially idle games, and rogue-like RPGs in China, QingCi has developed, published and operated a number of popular games. QingCi currently operates 6 mobile games and has a pipeline of 10 mobile games. Their landmark mobile games, such as The Marvelous Snail (最強蝸牛), Gumballs &amp; Dungeons (不思議迷宮) and Lantern and Dungeon (提燈與地下城), have recorded exceptional gross billings and achieved high rankings on the game lists widely recognized in the mobile game industry. <img src="../../../../../uploads/Qingci_EN_congrat_ad_7b330ac0be.PNG" alt="" width="533" height="400" /> <img src="../../../../../uploads/Qingci_live_c1e19c2d41.png" width="525" height="350" />

Congratulations to Qingci Games Inc. (6633.HK) on its Successful Listing

Hangzhou SF Intra-City Industrial Co., Ltd. (SF Intra-city) has been successfully listed on the Mainboard of HKSE. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. SF Intra-city is an on-demand delivery service provider in China. Started as a business unit of SF Holding Group in 2016, the company has operated as an independent legal entity since 2019, with a network covering over 1,000 cities and counties in China now. As of May 31, 2021, SF Intra-city cooperated with over 2,000 merchant brands and served more than 530,000 registered merchants. It is estimated that the annual order volume of on-demand delivery services in the industry will further increase to 29.2 billion in 2021, according to the iResearch Report. SF Intra-city had 513.7 million orders in the first 5 months of 2021. According to the rough estimate of the average daily orders, the market share of SF Intra-city has reached 4.3%, which is an almost four-fold increase compared to its 1.2% market share in 2019. SF Intra-city has also grown into the largest third-party on-demand delivery services platform in China with market share being 11.1% in the first 3 months in 2021. <img src="../../../../../uploads/congrat_ad_9699_EN_2663eac886.jpg" width="533" height="400" />

News